Treatment-Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924

Cancer Cell

Volumn 21, Issue 3, 2012, Pages 388-401

  Milhollen, Michael A ^a   Thomas, Michael P ^a   Narayanan, Usha ^a   Traore, Tary ^a   Riceberg, Jessica ^a   Amidon, Benjamin S ^a   Bence, Neil F ^a   Bolen, Joseph B ^a   Brownell, James ^a   Dick, Lawrence R ^a   Loke, Huay Keng ^a   McDonald, Alice A ^a   Ma, Jingya ^a   Manfredi, Mark G ^a   Sells, Todd B ^a   Sintchak, Mike D ^a   Yang, Xiaofeng ^a   Xu, Qing ^a   Koenig, Erik M ^a   Gavin, James M ^a   Smith, Peter G ^a   more..

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BORTEZOMIB; DOXORUBICIN; ENZYME; ENZYME INHIBITOR; MLN 4924; MUTANT PROTEIN; NEDD8 ACTIVATING ENZYME BETA; NEDD8 PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CHEMICAL ANALYSIS; COLON CANCER; COLORECTAL TUMOR; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME BINDING; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MELANOMA; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

EID: 84863338311     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.02.009     Document Type: Article

References (27)

1. Allen J.D., van Loevezijn A., Lakhai J.M., van der Valk M., van Tellingen O., Reid G., Schellens J.H., Koomen G.J., Schinkel A.H. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther. 2002, 1:417-425.
2. Brownell J.E., Sintchak M.D., Gavin J.M., Liao H., Bruzzese F.J., Bump N.J., Soucy T.A., Milhollen M.A., Yang X., Burkhardt A.L., et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol. Cell 2010, 37:102-111.
3. Bruzzese F.J., Tsu C.A., Ma J., Loke H.K., Wu D., Li Z., Tayber O., Dick L.R. Development of a charcoal paper adenosine triphosphate:pyrophosphate exchange assay: kinetic characterization of NEDD8 activating enzyme. Anal. Biochem. 2009, 394:24-29.
4. Choi Y.L., Soda M., Yamashita Y., Ueno T., Takashima J., Nakajima T., Yatabe Y., Takeuchi K., Hamada T., Haruta H., et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 2010, 363:1734-1739. ALK Lung Cancer Study Group.
5. Cortes J., Hochhaus A., Hughes T., Kantarjian H. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J. Clin. Oncol. 2011, 29:524-531.
6. Dantzig A.H., Shepard R.L., Cao J., Law K.L., Ehlhardt W.J., Baughman T.M., Bumol T.F., Starling J.J. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996, 56:4171-4179.
7. Gekeler V., Ise W., Sanders K.H., Ulrich W.R., Beck J. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem. Biophys. Res. Commun. 1995, 208:345-352.
8. Hyafil F., Vergely C., Du Vignaud P., Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993, 53:4595-4602.
9. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
10. Lin H.K., Chen Z., Wang G., Nardella C., Lee S.W., Chan C.H., Yang W.L., Wang J., Egia A., Nakayama K.I., et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010, 464:374-379.
11. Lin J.J., Milhollen M.A., Smith P.G., Narayanan U., Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res. 2010, 70:10310-10320.
12. Lu L., Ghose A.K., Quail M.R., Albom M.S., Durkin J.T., Holskin B.P., Angeles T.S., Meyer S.L., Ruggeri B.A., Cheng M. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors. Biochemistry 2009, 48:3600-3609.
13. Milhollen M.A., Traore T., Adams-Duffy J., Thomas M.P., Berger A.J., Dang L., Dick L.R., Garnsey J.J., Koenig E., Langston S.P., et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-kappaB-dependent lymphoma. Blood 2010, 116:1515-1523.
14. Milhollen M.A., Narayanan U., Soucy T.A., Veiby P.O., Smith P.G., Amidon B. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res. 2011, 71:3042-3051.
15. Nalepa G., Rolfe M., Harper J.W. Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov. 2006, 5:596-613.
16. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2:e73.
17. Sellers W.R. A blueprint for advancing genetics-based cancer therapy. Cell 2011, 147:26-31.
18. Schulman B.A., Harper J.W. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat. Rev. Mol. Cell Biol. 2009, 10:319-331.
19. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., Sawyers C.L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
20. Shalinsky D.R., Jekunen A.P., Alcaraz J.E., Christen R.D., Kim S., Khatibi S., Howell S.B. Regulation of initial vinblastine influx by P-glycoprotein. Br. J. Cancer 1993, 67:30-36.
21. Soucy T.A., Smith P.G., Milhollen M.A., Berger A.J., Gavin J.M., Adhikari S., Brownell J.E., Burke K.E., Cardin D.P., Critchley S., et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009, 458:732-736.
22. Soucy T.A., Smith P.G., Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin. Cancer Res. 2009, 15:3912-3916.
23. Swords R.T., Kelly K.R., Smith P.G., Garnsey J.J., Mahalingam D., Medina E., Oberheu K., Padmanabhan S., O'Dwyer M., Nawrocki S.T., et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010, 115:3796-3800.
24. Taverna P., Liu L., Hanson A.J., Monks A., Gerson S.L. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother. Pharmacol. 2000, 46:507-516.
25. Walden H., Podgorski M.S., Schulman B.A. Insights into the ubiquitin transfer cascade from the structure of the activating enzyme for NEDD8. Nature 2003, 422:330-334.
26. Wang M., Medeiros B.C., Erba H.P., DeAngelo D.J., Giles F.J., Swords R.T. Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. Expert Opin. Ther. Targets 2011, 15:253-264.
27. Watson I.R., Irwin M.S., Ohh M. NEDD8 pathways in cancer, sine quibus non. Cancer Cell 2011, 19:168-176.